Form 4: Bicycle Therapeutics Director Sands Receives Equity Grants

Bicycle Therapeutics PLC director Stephen H. Sands was granted 9,500 restricted share units and options to purchase 19,000 ordinary shares.

Summary

• Stephen H. Sands, a Director of Bicycle Therapeutics PLC, received equity grants on January 2, 2026.
• The grants include 9,500 Restricted Share Units (RSUs) and options to purchase 19,000 ordinary shares.
• Each RSU represents a contingent right to receive one ordinary share, with a reported acquisition price of $0.
• The stock options have an exercise price of $7.08 per share and an expiration date of January 2, 2036.
• Both the RSUs and stock options will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Following these transactions, Stephen H. Sands beneficially owns 26,893 ordinary shares and 19,000 derivative securities (stock options).
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating continued alignment of interests and commitment. It's a routine compensation event, not a major financial announcement, hence a moderate positive score.

Positives

• The grant of equity to Director Stephen H. Sands aligns his interests with those of shareholders.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged and systematic approach to equity compensation.

Negatives

• The issuance of new equity (upon vesting and exercise) could lead to minor dilution for existing shareholders.

Risks

• The value of the granted RSUs and stock options is subject to the future performance of Bicycle Therapeutics PLC's stock price.
• If the stock price does not exceed the option exercise price of $7.08, the options may not be 'in the money' and could expire worthless.

Future Outlook

The grants are structured with future vesting dates through December 2026, indicating a long-term incentive for the director. The stock options have a 10-year expiration, aligning the director's interests with long-term shareholder value creation.

Industry Context

Equity grants to directors are a standard practice across the biotechnology and pharmaceutical industries, aiming to align leadership incentives with company performance and shareholder value. This filing reflects a routine compensation event within this context.

Comparison to Industry Standards

• Equity compensation, including RSUs and stock options, is a common practice for non-executive directors in publicly traded biotechnology companies like Bicycle Therapeutics PLC.
• The vesting schedule over approximately one year is typical for such grants, designed to retain directors and incentivize sustained performance.
• The exercise price of $7.08 for the options would typically be the closing price on the grant date, which is standard for market-priced options.

Related Party Transactions

• The grant of 9,500 Restricted Share Units and 19,000 stock options to Stephen H. Sands, a Director of Bicycle Therapeutics PLC, represents a compensation-related transaction with a related party.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting and exercise of equity, but also improved alignment of director's interests with long-term shareholder value.
• Director (Stephen H. Sands): Receives significant equity incentives, increasing his stake and potential future compensation tied to company performance.

Next Steps

• Vesting of 9,500 RSUs in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Vesting of 19,000 stock options in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Potential exercise of stock options by Stephen H. Sands before January 2, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation. While it signals continued alignment of interests, it does not provide new fundamental information about the company's operational or financial performance that would warrant a change in investment recommendation. Investors should consider this as a standard disclosure and maintain their current position based on broader company fundamentals and market conditions.

Keywords

Bicycle Therapeutics, BCYC, Stephen H. Sands, Director, SEC Form 4, Restricted Share Units, RSU, Stock Options, Equity Grant, Beneficial Ownership, Rule 10b5-1, Insider Transaction